Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 7CNS 2Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Brain Neoplasms 12Central Nervous System Neoplasms 11Glioblastoma 10Gliosarcoma 8Glioma 7Astrocytoma 4Oligodendroglioma 3Neuroblastoma 3Melanoma 3Medulloblastoma 3Sarcoma 2Recurrence 2Osteosarcoma 2Neuroectodermal Tumors, Primitive 2Neoplasms 2Ependymoma 2Wilms Tumor 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma, Kaposi 1Sarcoma, Ewing 1Salivary Gland Neoplasms 1Rhabdomyosarcoma 1Retinoblastoma 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pinealoma 1

Interventions

Temozolomide 23Bevacizumab 18Cyclophosphamide 9Carboplatin 7Lomustine 6Irinotecan 63-Iodobenzylguanidine 6Topotecan 5Radiotherapy 5Filgrastim 5Radiosurgery 4Nivolumab 4Everolimus 4Etoposide 4Drug Therapy 4Busulfan 4sonidegib 3pembrolizumab 3olaparib 3fludarabine phosphate 3fludarabine 3cemiplimab 3antineoplaston AS 2-1 3antineoplaston A10 3Vincristine 3Thiotepa 3Sirolimus 3Melphalan 3IL13-PE38 3Antilymphocyte Serum 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recurrence × Thalidomide × CNS × Clear all
NCT01356290 2026-02-23

MEMMAT

Medical University of Vienna

Phase 2 Recruiting
232 enrolled
CNS

Ependymoma, Medulloblastoma, Recurrence

NCT00521482 2007-08-28

Temozolomide vs. Temozolomide and Thalidomide Treatment in Recurrent Glioblastoma

University of Zurich

Phase 2 Unknown
40 enrolled
CNS

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡